Rathbones Group PLC decreased its holdings in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) by 3.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 169,747 shares of the company’s stock after selling 5,837 shares during the quarter. Rathbones Group PLC’s holdings in Guardant Health were worth $30,276,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GH. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Guardant Health in the third quarter worth $892,000. Private Advisor Group LLC bought a new stake in shares of Guardant Health in the third quarter valued at about $233,000. OneAscent Financial Services LLC acquired a new stake in Guardant Health during the third quarter worth about $260,000. Stephens Investment Management Group LLC increased its stake in Guardant Health by 55.4% during the third quarter. Stephens Investment Management Group LLC now owns 395,281 shares of the company’s stock valued at $70,502,000 after acquiring an additional 140,971 shares during the period. Finally, Global Retirement Partners LLC lifted its position in shares of Guardant Health by 124.8% in the 3rd quarter. Global Retirement Partners LLC now owns 888 shares of the company’s stock worth $158,000 after acquiring an additional 493 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have recently issued reports on the company. TD Cowen restated a “buy” rating on shares of Guardant Health in a research report on Wednesday. Piper Sandler decreased their price target on shares of Guardant Health from $193.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 10th. Sanford C. Bernstein reissued an “outperform” rating and issued a $210.00 price target on shares of Guardant Health in a report on Thursday, September 10th. Barclays increased their price objective on shares of Guardant Health from $200.00 to $220.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Finally, Royal Bank Of Canada raised their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $191.48.
Check Out Our Latest Stock Analysis on GH
Guardant Health Trading Up 0.2%
Shares of GH opened at $145.83 on Friday. The stock has a market cap of $19.73 billion, a PE ratio of -39.63 and a beta of 1.67. Guardant Health, Inc. has a 1 year low of $74.55 and a 1 year high of $191.05. The stock has a 50 day simple moving average of $167.08 and a 200-day simple moving average of $133.80.
Guardant Health (NASDAQ:GH – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.75) by $0.46. The company had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same period in the prior year, the firm earned ($0.74) EPS. Guardant Health’s quarterly revenue was up 36.1% compared to the same quarter last year. On average, sell-side analysts forecast that Guardant Health, Inc. will post -3.28 EPS for the current fiscal year.
Insider Buying and Selling
In other news, CTO Darya Chudova sold 7,738 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total value of $1,377,364.00. Following the sale, the chief technology officer owned 70,635 shares of the company’s stock, valued at approximately $12,573,030. This represents a 9.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terilyn J. Monroe sold 3,842 shares of the stock in a transaction dated Wednesday, November 18th. The stock was sold at an average price of $142.41, for a total transaction of $547,139.22. Following the sale, the insider owned 21,058 shares of the company’s stock, valued at $2,998,869.78. This trade represents a 15.43% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 19,566 shares of company stock valued at $3,320,185 in the last ninety days. Insiders own 5.60% of the company’s stock.
Key Headlines Impacting Guardant Health
Investors following GH have been watching these headlines:
- Positive Sentiment: Stephens reaffirmed its “overweight” rating and set a $210 price target, signaling confidence in the stock’s prospects. Stephens stock recommendations
- Positive Sentiment: A recent report focused on raised guidance, which may bolster expectations for the company’s business outlook. What raised guidance means for shareholders
- Negative Sentiment: A separate commentary argues that GH looks richly priced after its recent run, raising the risk that valuation could limit further gains. Commentary on Guardant Health’s valuation
Guardant Health Profile
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Read More
- Five stocks we like better than Guardant Health
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.
